• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Genzyme

Genzyme

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. FDA Grants Fast Track Designation to Genzyme ’s Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease

    FDA Grants Fast Track Designation to Genzyme ’s Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease

  2. Research and Markets: Global Cell Therapy Market Outlook 2020

    Research and Markets: Global Cell Therapy Market Outlook 2020

  3. Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer

    Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer

  4. Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis

    Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis

  5. Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference

    Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference

  6. Alnylam Files Clinical Trial Application (CTA) for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

    Alnylam Files Clinical Trial Application (CTA) for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

  7. Veracyte Announces First Quarter 2015 Financial Results

    Veracyte Announces First Quarter 2015 Financial Results

  8. Alexion-Synageva Deal Shows Lure of Rare-Disease Drugs -- 3rd Update

    Alexion-Synageva Deal Shows Lure of Rare-Disease Drugs -- 3rd Update

  9. REITs, Target Dates, Dollar-Proofing, and More

    A roundup of investment news.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.